Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

CTXR Relative to the S&P 500

CTXR Relative to the Sector

% of Free Cash Flow Generated in Each Quarter

% of Net Income Generated in Each Quarter

Seasonal Chart Analysis

Analysis of the Citius Pharmaceuticals Inc. (NASD:CTXR) seasonal charts above shows that a Buy Date of November 25 and a Sell Date of April 6 has resulted in a geometric average return of 44.49% above the benchmark rate of the S&P 500 Total Return Index over the past 11 years. This seasonal timeframe has shown positive results compared to the benchmark in 9 of those periods. This is a very good rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 11 years by an average of 94.38% per year.

The seasonal timeframe correlates Poorly with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

Citius Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. Its products include I/ONTAK, Mino-Lok, Halo-Lido, Mino-Wrap, and Novecite. The company was founded by Ralph Montrone on January 23, 2007 and is headquartered in Cranford, NJ.

To download CTXR seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: CTXR